407 related articles for article (PubMed ID: 23948997)
1. Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial.
Tatebe S; Tsujitani S; Nakamura S; Shimizu T; Yamane N; Nishidoi H; Kurisu Y; Kanayama H; Ogawa H; Ikeguchi M
Gastric Cancer; 2014; 17(3):508-13. PubMed ID: 23948997
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of S-1 dosing schedule for resected colorectal cancer.
Matsuda C; Uemura M; Nakata K; Shingai T; Nishimura J; Hata T; Ikenaga M; Takemasa I; Mizushima T; Kato T; Ikeda M; Ohue M; Murata K; Hasegawa J; Satoh T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
BMC Cancer; 2015 Jun; 15():452. PubMed ID: 26036466
[TBL] [Abstract][Full Text] [Related]
3. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
Yoshikawa T; Terashima M; Mizusawa J; Nunobe S; Nishida Y; Yamada T; Kaji M; Fukushima N; Hato S; Choda Y; Yabusaki H; Yoshida K; Ito S; Takeno A; Yasuda T; Kawachi Y; Katayama H; Fukuda H; Boku N; Sano T; Sasako M
Lancet Gastroenterol Hepatol; 2019 Mar; 4(3):208-216. PubMed ID: 30679107
[TBL] [Abstract][Full Text] [Related]
4. [Alternate-day oral therapy with S-1 for adjuvant chemotherapy of gastric cancer].
Takebayashi K; Kawai Y; Tagi T; Matsumura M; Shimizu K; Yamamoto H; Mekata E; Tani T; Sato M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):385-7. PubMed ID: 22421764
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003).
Tanaka H; Kanda M; Morita S; Taguri M; Nishikawa K; Shimada M; Muguruma K; Koeda K; Takahashi M; Nakamori M; Konno H; Tsuji A; Hosoya Y; Shirasaka T; Yamamitsu S; Sowa M; Kitajima M; Okajima M; Kobayashi M; Sakamoto J; Saji S; Hirakawa K
Int J Clin Oncol; 2017 Dec; 22(6):1052-1059. PubMed ID: 28667408
[TBL] [Abstract][Full Text] [Related]
6. Optimal schedule of adjuvant chemotherapy with S-1 for stage III colon cancer: study protocol for a randomized controlled trial.
Yoshimura K; Uehara K; Tojima Y; Kawai S; Mokuno Y; Maeda A; Kyokane T; Kobayashi S; Yoshioka Y; Nagino M
Trials; 2013 Jan; 14():17. PubMed ID: 23320901
[TBL] [Abstract][Full Text] [Related]
7. A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703).
Kodera Y; Ishiyama A; Yoshikawa T; Kinoshita T; Ito S; Yokoyama H; Mochizuki Y; Ito H; Tsuburaya A; Sakamoto J; Nakao A;
Gastric Cancer; 2010 Aug; 13(3):197-203. PubMed ID: 20820990
[TBL] [Abstract][Full Text] [Related]
8. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301.
Okumura N; Soh J; Suzuki H; Nakata M; Fujiwara T; Nakamura H; Sonobe M; Fujinaga T; Kataoka K; Gemba K; Kataoka M; Hotta K; Yoshioka H; Matsuo K; Sakamoto J; Date H; Toyooka S
BMC Cancer; 2021 May; 21(1):506. PubMed ID: 33957881
[TBL] [Abstract][Full Text] [Related]
10. Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.
Hata Y; Kiribayashi T; Kishi K; Nagashima M; Nakayama T; Ikeda S; Kadokura M; Ozeki Y; Otsuka H; Murakami Y; Takagi K; Iyoda A
BMC Cancer; 2017 Aug; 17(1):581. PubMed ID: 28851314
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
[TBL] [Abstract][Full Text] [Related]
12. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
13. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
[TBL] [Abstract][Full Text] [Related]
14. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer.
Kawahara H; Watanabe K; Ushigome T; Noaki R; Kobayashi S; Yanaga K
Hepatogastroenterology; 2012; 59(113):134-7. PubMed ID: 22251528
[TBL] [Abstract][Full Text] [Related]
15. Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer.
Kim SJ; Kim YJ; Kim JH; Park DJ; Kim HH; Lee JS; Lee KW
Cancer Sci; 2013 Jan; 104(1):116-23. PubMed ID: 23066919
[TBL] [Abstract][Full Text] [Related]
16. Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding.
Fujitani K; Tsujinaka T; Hirao M
Hepatogastroenterology; 2003; 50(51):889-92. PubMed ID: 12828112
[TBL] [Abstract][Full Text] [Related]
17. Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity.
Sakuma K; Hosoya Y; Arai W; Haruta H; Ui T; Kurashina K; Saito S; Hirashima Y; Yokoyama T; Zuiki T; Hyodo M; Nagai H; Yasuda Y; Shirasaka T
Int J Clin Oncol; 2010 Apr; 15(2):166-71. PubMed ID: 20195683
[TBL] [Abstract][Full Text] [Related]
18. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
[TBL] [Abstract][Full Text] [Related]
19. Feasibility study of S-1 adjuvant chemotherapy in patients with colorectal cancer.
Ogawa M; Watanabe M; Kobayashi T; Eto K; Oda A; Anan T; Hayashi T; Mitsuyama Y; Yanaga K
Int J Clin Oncol; 2013 Aug; 18(4):678-83. PubMed ID: 22585427
[TBL] [Abstract][Full Text] [Related]
20. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer.
Yamaue H; Shimizu A; Hagiwara Y; Sho M; Yanagimoto H; Nakamori S; Ueno H; Ishii H; Kitano M; Sugimori K; Maguchi H; Ohkawa S; Imaoka H; Hashimoto D; Ueda K; Nebiki H; Nagakawa T; Isayama H; Yokota I; Ohashi Y; Shirasaka T
Cancer Chemother Pharmacol; 2017 Apr; 79(4):813-823. PubMed ID: 28251282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
